REG - ValiRx PLC - Statement re social media reports

ValiRxAnnouncement

29/04/2020 17:45

RNS Number : 3894L
  
ValiRx PLC
  
29 April 2020
  
 

VALIRX PLC
("ValiRx", the "Company" or the "Group")
 
Statement re social media reports
 
London, UK., 29 April 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, notes the recent movement in the Company's share price and speculative comments posted on social media in respect of a potential Joint Venture in relation to the Company's non-core intellectual property - GeneICE, TRAC and BioFit.
 
The Company confirms that it is in talks with a third-party in relation to a Joint Venture.  However, there is no certainty the talks will conclude in a successful manner, nor that in the event that the Joint Venture is agreed, that the terms will be favourable to the Company.
 
-ENDS-
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 
 
For more information, please contact:
 



ValiRx plc


Tel: +44 (0)207 0732628
www.valirx.com




Kevin Alexander - Non-executive Director








Cairn Financial Advisers LLP (Nominated Adviser) 
Liam Murray / Jo Turner / Ludovico Lazzaretti
 


Tel: +44 (0) 20 7213 0880




Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker 
 


Tel: +44 (0) 20 7469 0930



 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCSEUFMUESSEDL